Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

CervoMed (CRVO) EBIT (2022 - 2025)

CervoMed (CRVO) has disclosed EBIT for 9 consecutive years, with -$8.3 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 15.06% to -$8.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$28.3 million through Dec 2025, down 55.23% year-over-year, with the annual reading at -$28.3 million for FY2025, 55.23% down from the prior year.
  • EBIT hit -$8.3 million in Q4 2025 for CervoMed, down from -$8.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$904054.0 in Q3 2022 to a low of -$8.3 million in Q4 2025.
  • Historically, EBIT has averaged -$4.1 million across 4 years, with a median of -$3.6 million in 2022.
  • Biggest YoY gain for EBIT was 71.01% in 2023; the steepest drop was 195.9% in 2023.
  • Year by year, EBIT stood at -$938823.0 in 2022, then tumbled by 164.21% to -$2.5 million in 2023, then tumbled by 191.92% to -$7.2 million in 2024, then dropped by 15.06% to -$8.3 million in 2025.
  • Business Quant data shows EBIT for CRVO at -$8.3 million in Q4 2025, -$8.0 million in Q3 2025, and -$6.6 million in Q2 2025.